Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference53 articles.
1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92. doi: 10.1111/j.1742-1241.2011.02799.x .
2. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59. doi: 10.1200/jco.2007.12.4487 .
3. Integraal Kankercentrum Nederland. Prostaatcarcinoom: Landelijke Richtlijn, Versie: 2.0.; 2014.
4. Mottet N (Chair), Briers E (Patient Representative), Bolla M, Cornford P (Vice-chair), De Santis M, et al. Guideline prostate cancer. European Association of Urology. 2016. http://uroweb.org/guideline/prostate-cancer/ . Accessed 25 Aug 2017.
5. Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 2015;12(6):340–56. doi: 10.1038/nrurol.2015.90 .
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献